

Supplementary Information

Antioxidant and anti-aging potential of a peptide formulation (Gal2-Pep) conjugated with gallic acid

Hoomin Lee^{a,§}, Kwanwoo Kim^{a,§}, Cheolwoo Oh^a, Chi-Hu Park^b, Sheik Aliya^a, Hyoungh Shik Kim^b, Vivek K. Bajpai^{c,*}, Yun Suk Huh^{a,*}

^a Department of Biological Sciences and Bioengineering, Nano Bio High-Tech Materials Research Center, Inha University, Incheon 22212, Republic of Korea

^b Natural Bioactive & Anticancer Research Institute, YEPBio Co., Ltd., Suwon 16229, Republic of Korea

^c Department of Energy and Materials Engineering, Dongguk University, 30 Pildong-ro 1-gil, Seoul 04620, Republic of Korea

§ These authors contributed equally to this work.

Running head: Biologically active peptide formulation

Corresponding author:

vbitech04@gmail.com (V. K. Bajpai); yunsuk.huh@inha.ac.kr (Y. S. Huh)




Figure S1. HPLC peak of purified (Galloyl)₂-KTPPTTP. Analytical reverse-phase high-performance liquid chromatography (RP-HPLC) was conducted on a Waters 2695 Separations Module with a Capcell Pak C18 column (4.6 mm x 250 mm, 5 μm, Shiseido). The mobile phase consisted of 0.05% TFA in H₂O (mobile phase A) and 0.05% TFA in acetonitrile (mobile phase B). Elution was achieved by employing a linear gradient for mobile phase B of 5% to 65% over 30 min at a flow rate of 1.0 mL/min. The peptide peaks were detected at a wavelength of 230 nm.




Figure S2. Evaluation of cell viability for final purified peptide sample using MTT assay: a) HaCaT, b) CCD-1064sk.




Figure S3. Evaluation of cell viability for final purified peptide sample using LDH assay: a) HaCaT, b) CCD-1064sk.




Figure S4. Inflammation evaluation on RAW 264.7 cells of the final purified peptide using Griess reagent. LPS (lipopolysaccharide) as an inflammation inducer and L-NMMA as a NOS inhibitor.